Salix Pharmaceuticals Ltd

Salix Pharmaceuticals — Inkine Pharmaceutical — Merger or Acquisition (July 2005)

24 slides from Salix Pharmaceuticals's merger presentation, Jul 19, 2005

  1. Slide 1: Creating the Largest Specialty Pharmaceutical Company Focused on Gastroenterologists

    Creating the Largest Specialty Pharmaceutical Company Focused on Serving U.S. Gastroenterologists and Their Patients July 2005

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains forward-looking statements regarding future events including statements regarding the effect of the transaction to EPS, the benefits of the merger to InKine and Salix and to each of their stockholders, the timing of completion of the transaction a

  3. Slide 3: Deal Summary

    Deal Summary Salix and InKine have agreed to merge and create the largest pure-play specialty pharmaceutical company focused on gastroenterology Type of transaction: Stock-for-Stock Exchange Offer price per InKine share: $3.55 Fixed price collar arrangement Implied value of transaction: $190.0 milli

  4. Slide 4: Salix – Well Positioned for Future Growth Opportunities

    Salix – Well Positioned for Future Growth Opportunities Dedicated to becoming the leading specialty pharmaceutical company in the gastroenterology market COLAZAL® continues to be the fastest-growing oral branded 5-ASA with 2004 sales of $85.4 million Focused on maximizing shareholder value through r

  5. Slide 5: Overview of U.S. Gastroenterology Market

    Market Overview of U.S. Gastroenterology Market Small target audience (12,000 physicians) 31.4 million patient visits annually 38 million prescriptions annually $4.8 billion Rx sales annually Source: Verispan PDDA and NDCHealth PHAST (2004)

  6. Slide 6: Key Products Fuel Strong Sales Growth for Salix

    Key Products Fuel Strong Sales Growth for Salix Products Indication Comments Mildly to moderately $85.4 million in 2004 sales active ulcerative colitis Travelers’ diarrhea ALTANA Pharma co-promote $in millions TOTAL PRODUCT REVENUES $160 120 80 40 0 $14 $34 $56 $102 $150—$155 2001 2002 2003 2004 200

  7. Slide 7: An Introduction to InKine

    An Introduction to InKine

  8. Slide 8: InKine – Uniquely Positioned in the Colonoscopy Market

    InKine – Uniquely Positioned in the Colonoscopy Market Strong Presence in the Colonoscopy Preparation Market VISICOL®—the first and only purgative tablet INKP-102 is the next generation purgative tablet 50-person sales force targeting high prescribing gastroenterologists Profitable and cash flow pos

  9. Slide 9: Visicol – The First and Only Purgative Tablet

    Visicol® – The First and Only Purgative Tablet Launched in January 2001 Advantages Virtually tasteless Significantly less nausea, vomiting, and bloating Taken with any clear fluid High patient compliance with approximately 92% of patients completing the VISICOL® prep High patient acceptance Greater

  10. Slide 10: Visicol – Competing Products

    Visicol® – Competing Products Competing PEG solutions / Sodium Phosphate Solutions Require 1—4 liters of liquid and have an unpleasant after-taste Frequently cause undesirable symptoms

  11. Slide 11: INKP-102 – Near-Term Value Driver

    INKP-102 – Near-Term Value Driver Potential Benefits Microcrystalline cellulose (MCC) free Smaller tablets Possible lower-dose administration

  12. Slide 12: INKP-102 – Near-Term Value Driver

    INKP-102 – Near-Term Value Driver Positive results from Phase II and III clinical trials submitted as SPA (Special Clinical Protocol Assessment) Submitted NDA to FDA on April 29, 2005 for use as a preparation for colonoscopy Filed U.S. patent application on November 16, 2004 – if issued, product wil

  13. Slide 13: Colonoscopy Market Growth Drivers

    Colonoscopy Market Growth Drivers Demographics Aging population Poorly-penetrated market – only 50% of Americans over the age of 50 have received colorectal cancer testing Public awareness Colon cancer awareness initiatives Expanded Medicare and other third-party reimbursement Medical practice Colon

  14. Slide 14: Bowel Preparation Market Potential

    Bowel Preparation Market Potential 7.0 million bowel prep procedures estimated for 2004 4.5 million prescriptions for May 2005 TTM Approximately $115 million sales May 2005 TTM Source: IMS Data, NDC Health PHAST

  15. Slide 15: Near-Term Value Driver – Visicol / INKP-102 for Constipation

    Near-Term Value Driver – Visicol® / INKP-102 for the Treatment of Constipation InKine met with FDA in January 2005 on development program for a constipation label amendment for VISICOL Phase IV conclusions Low dose therapy with VISICOL is highly effective in treating constipation Treatment was assoc

  16. Slide 16: Constipation Market Overview

    Constipation Market Overview Total U.S. market for prescription drugs: $697 million 61% CAGR in prescription market from May 2002 – May 2005 Launch of new products Aggressive treatment of severe constipation Aging population Source: NDC Health PHAST

  17. Slide 17: A Compelling Combination

    A Compelling) Combination 7

  18. Slide 18: The Vision: Largest Pure-Play GI-Focused Specialty Pharmaceutical Company

    The Vision: Creation of the Largest Pure-Play GI-Focused Specialty Pharmaceutical Company Expanded presence in the gastroenterology market Enhanced position relative to future acquisition / partnering opportunities Complementary sales force Combined product pipeline creates strong near- and long-ter

  19. Slide 19: Transaction Rationale

    Transaction Rationale Strategic Enhanced position in the U.S. gastroenterology market Operational Leverage infrastructure to maximize adoption of key products Product Broader portfolio of patent protected GI products to fuel growth

  20. Slide 20: Transaction Rationale - Strategic

    Transaction Rationale -Strategic A combination with excellent strategic “fit” and clear rationale Creation of the largest GI-focused specialty pharmaceutical company (approaching $1.0 billion in market value) Established product development / business development effort will enhance the ability to p

  21. Slide 21: Transaction Rationale - Operational

    Transaction Rationale -Operational The largest and most well respected specialty sales force in the GI industry Powerful commercialization effort with combined sales force of approximately 100 sales representatives VISICOL has strong growth potential over the longer term and can benefit immediately

  22. Slide 22: Transaction Rationale - Product

    Transaction Rationale -Product Combined product pipeline should create strong growth prospects and drive revenue from a wider array of products Three phase III / NDA candidates and numerous additional indications being pursued for commercial products Broader product portfolio will help mitigate risk

  23. Slide 23: A Compelling Combination in Salix and InKine – Investment Highlights

    A Compelling Combination in Salix and InKine – Investment Highlights Substantial portfolio of marketed products COLAZAL® VISICOL® XIFAXAN™ AZASAN® ANUSOL-HC® & PROTOCORT® Late-stage follow-on products INKP-102 – bowel prep Granulated Mesalamine XIFAXAN™—various potential uses COLAZAL® Tablet VISICOL

  24. Slide 24: Additional Information about the Merger

    In connection with the merger between Salix and InKine, on July 18, 2005 Salix filed with the SEC a registration statement on Form S-4, containing a preliminary joint proxy statement/prospectus and other relevant materials. INVESTORS AND SECURITY HOLDERS OF SALIX AND INKINE ARE URGED TO READ THE DEF

Inkine Pharmaceutical — Merger or Acquisition (July 2005) on 6ix